BEIJING SINOGENETIC BIOTECHNOLOGY

Beijing Sinogenetic Biotechnology Co., Ltd. was established in 2021. Relying on the parent company's animal cloning and gene editing technology platform, the company has developed and constructed multi-species (dog/pig/cat/rabbit/mouse/rat) gene editing animal models, set up drug analysis and evaluation platforms such as pharmacological efficacy, pharmaco toxicology and safety evaluation, and established multi-omics analysis, imaging electrophysiology and behavioral analysis platforms. For , It provides full-process services of preclinical CRO based on multi-breed gene editing model animal development and application for drug development and device evaluation, especially for innovative drug development such as gene therapy and cell therapy.

Also known as: Beijing Sinogenetic Biotechnology Co., Ltd